Granted Patent B2

US 12,599,577 · App. 17/281,647 · Granted Apr 14, 2026

Inventors: Morgan Virginia Fedorchak (Mars, PA); Steven R. Little (Allison Park, PA); Joel S. Schuman (New York, NY)

Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

A61K31/145A61K9/0048A61K9/06A61K9/1647A61K9/1694A61K41/0028A61K47/32A61P27/02

Abstract

Claims (18)

1 . An ocular delivery system for cysteamine, comprising:

a thermoresponsive gel comprising poly(N-isopropyl acrylamide) (PNIPAAm); and

a plurality of spray-dried microparticles comprising a biodegradable polymer and cysteamine or a pharmaceutically acceptable salt thereof, wherein said biodegradable polymer comprises poly(lactic-co-glycolic acid) (PLGA),

wherein at least 90 percent of said cysteamine or said pharmaceutically acceptable salt thereof is maintained within said ocular delivery system for at least seven weeks at 25° C.

2 . The ocular delivery system of claim 1 , wherein the biodegradable polymer comprises polyglycolide (PGA), poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), or any combination thereof.

3 . The ocular delivery system of claim 1 , wherein the cysteamine or the pharmaceutically acceptable salt thereof is homogeneously dispersed within the spray-dried microparticles.

4 . The ocular delivery system of claim 1 , wherein the spray-dried microparticles have a volume average diameter within a range of from 200 nm to 10 μm.

5 . The ocular delivery system of claim 1 , wherein the spray-dried microparticles comprise from 10-20 wt % cysteamine or an amount of a pharmaceutically acceptable salt of cysteamine sufficient to provide 10-20 wt % cysteamine.

6 . The ocular delivery system of claim 1 , wherein the PLGA has a weight average molecular weight within a range of 4-80 kDa.

7 . The ocular delivery system of claim 1 , wherein the ocular delivery system comprises from 0.001 mg to 0.5 mg of the spray-dried microparticles per microliter of the ocular delivery system.

8 . An ocular delivery system for cysteamine made by a process comprising:

providing a liquid feedstock comprising cysteamine or a pharmaceutically acceptable salt thereof, a biodegradable polymer, and a solvent, wherein the biodegradable polymer comprises poly(lactic-co-glycolic acid) (PLGA);

directing the liquid feedstock to a spray-drying apparatus comprising a drying chamber comprising an inlet and an outlet, a nozzle coupled to the inlet, a spray gas source coupled to the nozzle, a separator coupled to the outlet of the drying chamber, and an aspirator coupled to the separator;

atomizing the liquid feedstock into droplets as the liquid feedstock flows through the nozzle and into the drying chamber;

removing at least a portion of the solvent from the droplets in the drying chamber, thereby forming a plurality of spray-dried microparticles, wherein the spray-dried microparticles comprise a solid dispersion of the cysteamine, or the pharmaceutically acceptable salt thereof, and the biodegradable polymer;

collecting the spray-dried microparticles; and

dispersing the spray-dried microparticles in a thermoresponsive gel comprising poly(N-isopropyl acrylamide) (PNIPAAm) to form an ocular delivery system for cysteamine,

wherein at least 90 percent of said cysteamine or said pharmaceutically acceptable salt thereof is maintained within said ocular delivery system for at least seven weeks at 25° C.

Assignments (2)

Continuity (2)

References Cited (130)